Literature DB >> 9523497

Comparison of the EQ-5D and SF-12 in an adult US sample.

J A Johnson1, S J Coons.   

Abstract

The purpose of this paper is to discuss the results of a direct comparison of two instruments, the SF-12 health survey and the EuroQol Group's EQ-5D, in a sample drawn from the adult US population. The data were collected via a survey instrument mailed to 1,800 subjects in the USA. The instrument contained the EQ-5D valuation questionnaire and the items of the SF-12. In addition, the subjects were asked to provide demographic information, complete a depression screening item and to indicate if they had any of seven common chronic conditions. The usable response rate was 23.7%. Patients indicating a health problem on the EQ-5D had significantly lower mean SF-12 component scores (i.e. MCS-12 and PCS-12) for all dimensions. As was expected, the relationships were stronger between the EQ-5D functional dimensions and the PCS-12 and between the MCS-12 and the EQ-5D anxiety/depression dimension. The EQ-5D visual analogue scale (VAS) scores were positively correlated with both component scores; r = 0.55 for PCS-12 and r = 0.41 for MCS-12. The results of this investigation provide support for the validity of both the EQ-5D and the SF-12 as descriptive measures of health status. The measurements by both instruments behaved in patterns that were consistent with recognized sociodemographic differences in health status. The limitations of the dimensional structure of the EQ-5D were somewhat overcome by the use of the VAS, which may also be possible with a constructed index score based on explicit values derived from a general population. The SF-12 appeared to be more sensitive to differences associated with less severe morbidity.

Entities:  

Mesh:

Year:  1998        PMID: 9523497     DOI: 10.1023/a:1008809610703

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  8 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  Valuation of EuroQOL (EQ-5D) health states in an adult US sample.

Authors:  J A Johnson; S J Coons; A Ergo; G Szava-Kovats
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

3.  EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway.

Authors:  E Nord
Journal:  Health Policy       Date:  1991-06       Impact factor: 2.980

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

5.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

Authors:  J Ware; M Kosinski; S D Keller
Journal:  Med Care       Date:  1996-03       Impact factor: 2.983

6.  Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire.

Authors:  J Brazier; N Jones; P Kind
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

Review 7.  Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life.

Authors:  D A Revicki; R M Kaplan
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

8.  EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise.

Authors:  R G Brooks; S Jendteg; B Lindgren; U Persson; S Björk
Journal:  Health Policy       Date:  1991-06       Impact factor: 2.980

  8 in total
  108 in total

Review 1.  A comparative review of generic quality-of-life instruments.

Authors:  S J Coons; S Rao; D L Keininger; R D Hays
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

2.  Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication.

Authors:  J L Bosch; M G Hunink
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

3.  Swedish population health-related quality of life results using the EQ-5D.

Authors:  K Burström; M Johannesson; F Diderichsen
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

4.  Adjusting distributions of the Health Utilities Index Mark 3 utility scores of health-related quality of life.

Authors:  Jian Sun
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

5.  Understanding differences between self-ratings and population ratings for health in the EuroQOL.

Authors:  Ralph P Insinga; Dennis G Fryback
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

6.  Impact of musculoskeletal co-morbidity of neck and upper extremities on healthcare utilisation and sickness absence for low back pain.

Authors:  W IJzelenberg; A Burdorf
Journal:  Occup Environ Med       Date:  2004-10       Impact factor: 4.402

7.  Discriminative capacity of the EQ-5D, SF-6D, and SF-12 as measures of health status in population health survey.

Authors:  Oriol Cunillera; Ricard Tresserras; Luis Rajmil; Gemma Vilagut; Pilar Brugulat; Mike Herdman; Anna Mompart; Antonia Medina; Yolanda Pardo; Jordi Alonso; John Brazier; Montse Ferrer
Journal:  Qual Life Res       Date:  2010-03-31       Impact factor: 4.147

8.  Health-related quality of life in Chinese patients with chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Fei-Li Zhao; Ming Yue; Hua Yang; Tian Wang; Jiu-Hong Wu; Shu-Chuen Li
Journal:  Qual Life Res       Date:  2010-06-24       Impact factor: 4.147

9.  Construct validity of the SF-12 among American Indian and Alaska Native people using two known scoring methods.

Authors:  Sandra L Edwards; Molly McFadden; Anne P Lanier; Maureen A Murtaugh; Elizabeth D Ferucci; Diana G Redwood; Lillian Tom-Orme; Martha L Slattery
Journal:  J Health Care Poor Underserved       Date:  2012-08

10.  Psychometric properties of the EQ-5D-5L in the general population of South Korea.

Authors:  Tae Hyup Kim; Min-Woo Jo; Sang-il Lee; Seon Ha Kim; Son Mi Chung
Journal:  Qual Life Res       Date:  2012-12-06       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.